Top

Cancer Cell International

Published in:

Open Access 01-12-2021 | Breast Cancer | Primary research

Carboxypeptidase N1 is anticipated to be a synergy metrics for chemotherapy effectiveness and prognostic significance in invasive breast cancer

Authors: Ranliang Cui, Chaomin Wang, Tiantian Li, Jialei Hua, Ting Zhao, Li Ren, Yichao Wang, Yueguo Li

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

The incidence and mortality of invasive breast cancer (IBC) are increasing annually. Hence, it is urgently needed to determine reliable biomarkers for not only monitoring curative effects, but evaluating prognosis. In present study, we aim to determine the potential role of Carboxypeptidase N1 (CPN1) in IBC tissues on chemotherapeutic efficacy and poor prognosis.

Methods

The expression level of CPN1 in IBC tissue samples (n = 123) was quantified by tissue microarray technique and immunohistochemical staining. Moreover, sera of IBC patients (n = 34) that underwent three to five consecutive chemotherapy sessions were collected. The patients were randomly stratified into a training (n = 15) as well as a validation group (n = 19). The expression of serum CA153 and CPN1 was quantified by electrochemiluminescence and ELISA assay, respectively.

Results

By univariate and multivariate Cox regression analysis, we show that CPN1 expression in IBC tissues, as an independent risk factor, is related to a poor overall survival (OS) and progression-free survival (PFS) (P < 0.05). Analysis of the data revealed that CPN1 over-expression could be consistently linked to adverse clinicopathological features such as lymph node metastasis and the pathological stage (pTNM) (P < 0.05). The serum CPN1 level trajectory of individual patients generally decreased during chemotherapy. In line with these findings were changes in the follow-up ultrasonography and a consistent decrease in serum CPN1 levels. The comparison of the area under the receiver operating curves (ROC) revealed that CPN1 has a better surveillance value than CA153 in the training (AUC_CPN1 = 0.834 vs. AUC_CA153= 0.724) as well as the validation set (AUC_CPN1 = 0.860 vs. AUC_CA153 = 0.720) when comparing cycle2 versus cycle3.

Conclusions

CPN1 is a suitable potential biomarker for chemotherapeutic surveillance purposes as well as being an appropriate prognostic indicator which would support an improved chemotherapy regimen.

Available only for authorised users

Wang LL, Zhang SZ, Wang XC. The metabolic mechanisms of breast cancer metastasis. Front Oncol. 2021;01(07):2416–8. https://doi.org/10.3389/fonc.2020.602416.CrossRef

Medeiros B, Allan AL. Molecular mechanisms of breast cancer metastasis to the lung: clinical and experimental perspectives. Int J Mol Sci. 2019;20(9):2272–2272. https://doi.org/10.3390/ijms20092272.CrossRefPubMedCentral

Tellez-Gabriel M, Knutsen E, Perander M. Current status of circulating tumor cells, circulating tumor DNA, and exosomes in breast cancer liquid biopsies. Int J Mol Sci. 2020;21(24):9457–80. https://doi.org/10.3390/ijms21249457.CrossRefPubMedCentral

Zhang JJ, Mao F, Niu G, Peng L, Lang LX, Li F, et al. ⁶⁸Ga-BBN-RGD PET/CT for GRPR and Integrin α_vβ₃ imaging in patients with breast cancer. Theranostics. 2018;8(4):1121–30. https://doi.org/10.7150/thno.22601.CrossRefPubMedPubMedCentral

Yang DP, Zhuang BW, Wei W, Xie XY, Xie XH. Differential diagnosis of liver metastases of gastrointestinal stromal tumors from colorectal cancer based on combined tumor biomarker with features of conventional ultrasound and contrast-enhanced ultrasound. Abdom Radiol. 2020;45(9):2717–25. https://doi.org/10.1007/s00261-020-02592-6.CrossRef

Tang ZJ, Li L, Shen L, Shen XJ, Ju SQ, Cong H. Diagnostic value of serum concentration and integrity of circulating cell-free DNA in breast cancer: a comparative study with CEA and CA15-3. Lab Med. 2018;49(4):323–8. https://doi.org/10.1093/labmed/lmy019.CrossRefPubMed

Ideo H, Hinoda Y, Sakai K, Hoshi I, Yamamoto S, Oka M, et al. Expression of mucin 1 possessing a 3’-sulfated core1 in recurrent and metastatic breast cancer. Int J Cancer. 2015;137(7):1652–60. https://doi.org/10.1002/ijc.29520.CrossRefPubMed

Lobo J, Leão R, Jerónimo C, Henrique R. Liquid biopsies in the clinical management of germ cell tumor patients: state-of-the-art and future directions. Int J Mol Sci. 2021;22(5):2654–2654. https://doi.org/10.3390/ijms22052654.CrossRefPubMedPubMedCentral

Schochter F, Friedl TWP, deGregorio A, Krause S, Huober J, Rack B, et al. Are circulating tumor cells (CTCs) ready for clinical use in breast cancer? An overview of completed and ongoing trials using CTCs for clinical treatment decisions. Cells. 2019;8(11):1412–21. https://doi.org/10.3390/cells8111412.CrossRefPubMedCentral

10.

Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol. 2020;11(155):3109–25. https://doi.org/10.1016/j.critrevonc.2020.103109.CrossRef

11.

Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019;1871(2):455–68. https://doi.org/10.1016/j.bbcan.2019.04.004.CrossRefPubMedPubMedCentral

12.

Davis AA, Zhang Q, Gerratana L, Shah AN, Zhan Y, Qiang W, et al. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Breast Cancer Res. 2019;21(1):137.CrossRef

13.

Song XQ, Liang B, Wang CG, Shi S. Clinical value of color Doppler ultrasound combined with serum CA153, CEA and TSGF detection in the diagnosis of breast cancer. Exp Ther Med. 2020;20(2):542–53. https://doi.org/10.3892/etm.2020.8868.CrossRef

14.

Li YJ, Li YG, Chen T, Kuklina A, Bernard P, Francisco J, et al. Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer. Clinial Chemistry. 2014;60(1):233–42. https://doi.org/10.1373/clinchem.2013.211953.CrossRef

15.

Leung LLK, Morser J. Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity. J Thromb Haemost. 2018;16(10):1474–86. https://doi.org/10.1111/jth.14199.CrossRef

16.

Cui R, Wang C, Zhao Q, Wang YC, Li YG. Serum carboxypeptidase N1 serves as a potential biomarker complementing CA15-3 for breast cancer. Anti-Cancer Agents Med Chem. 2020;35(04):639–42. https://doi.org/10.2174/1871520620666200703191135.CrossRef

17.

Ahmed FS, Dercle L, Goldmacher GV, Yang H, Connors D, Tang Y, et al. Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. Eur Radiol. 2021;31(4):1853–62. https://doi.org/10.1007/s00330-020-07249-y.CrossRefPubMed

18.

Cui RL, Zhang P, Li YG. Role of carboxypeptidase n invasion and migration in breast cancer. Anti-Cancer Agents Med Chem. 2016;16(9):1198–202. https://doi.org/10.2174/1871520616666160201104939.CrossRef

19.

Lin HY, Chu PY. Advances in understanding mitochondrial MicroRNAs (mitomiRs) on the pathogenesis of triple-negative breast cancer (TNBC). Oxid Med Cell Longev. 2021;13(09):1322–32. https://doi.org/10.1155/2021/5517777.CrossRef

20.

Zhang Z, Tang P. Genomic pathology and biomarkers in breast cancer. Crit Rev Oncog. 2017;22(5–6):411–26. https://doi.org/10.1615/CritRevOncog.v22.i5-6.60.CrossRefPubMed

21.

Liu Y, Teng L, Fu S, Wang GY, Li ZJ, Ding C. Highly heterogeneous- related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers. BMC Cancer. 2021;21(1):644–644. https://doi.org/10.1186/s12885-021-08318-1.CrossRefPubMedPubMedCentral

22.

Cao L, Niu Y. Triple negative breast cancer: special histological types and emerging therapeutic methods. Cancer Biol Med. 2020;17(2):293–306. https://doi.org/10.20892/j.issn.2095-3941.2019.0465.CrossRefPubMedPubMedCentral

23.

Wang ZY, Jiang QJ, Dong CF. Metabolic reprogramming in triple-negative breast cancer. Cancer Biol Med. 2020;17(1):44–59. https://doi.org/10.20892/j.issn.2095-3941.2019.0210.CrossRefPubMedPubMedCentral

24.

de Almeida FK, Rosa DD. Adjuvant dose-dense chemotherapy for breast cancer: available evidence and recent updates. Breast Care. 2018;13(6):447–52.CrossRef

25.

Li Q, Wang J, Mu Y, Zhang TT, Han Y, Wang JY, et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chin J Cancer Res. 2020;32(4):485–96. https://doi.org/10.21147/j.issn.1000-9604.2020.04.06.CrossRefPubMedPubMedCentral

26.

Matikas A, Foukakis T, Bergh J. Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts. Acta Oncol. 2017;56(9):1143–51. https://doi.org/10.1080/0284186X.2017.1329593.CrossRefPubMed

27.

Blondeaux E, Poggio F, Del Mastro L. Role of dose-dense chemotherapy in high-risk early breast cancer. Curr Opin Oncol. 2019;31(6):480–5. https://doi.org/10.1097/CCO.0000000000000571.CrossRefPubMed

28.

Furlanetto J, Loibl S. Optimal systemic treatment for early triple-negative breast cancer. Breast Care. 2020;15(3):217–26. https://doi.org/10.1159/000508759.CrossRefPubMedPubMedCentral

29.

Xie Q, Xiao YS, Jia SC, Zheng JX, Du ZC, Chen YC, et al. FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer. Cancer Cell Int. 2020;20:562. https://doi.org/10.1186/s12935-020-01656-3 (Published online 2020 Nov 23).CrossRefPubMedPubMedCentral

30.

Shah K, Rawal RM. Genetic and epigenetic modulation of drug resistance in cancer: challenges and opportunities. Curr Drug Metab. 2019;20(14):1114–31. https://doi.org/10.2174/1389200221666200103111539.CrossRefPubMed

31.

Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2020;11(215):1–21. https://doi.org/10.1016/j.febslet.2005.12.060.CrossRef

32.

Gao L, Zhao P, Li Y, Yang DW, Hu P, Li LZ, et al. Reversal of P-glycoprotein-mediated multidrug resistance by novel curcumin analogues in paclitaxel-resistant human breast cancer cells. Biochem Cell Biol. 2020;98(4):484–91. https://doi.org/10.1139/bcb-2019-0377.CrossRefPubMed

33.

Zhang S, Zhou L, Zhang M, Wang YH, Wang MQ, Du JC, et al. Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin. Front Pharmacol. 2020;1(10):3389–404. https://doi.org/10.3389/fphar.2019.01658.CrossRef

34.

Kobayashi A, Suzuki Y, Sugai S. Specificity of transaminase activities in the prediction of drug-induced hepatotoxicity. J Toxicol Sci. 2020;45(9):515–37. https://doi.org/10.2131/jts.45.515.CrossRefPubMed

35.

Vincenzi B, Armento G, Spalato Ceruso M, Catania G, Leakos M, Santini D, et al. Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opin Drug Saf. 2016;15(9):1219–38. https://doi.org/10.1080/14740338.2016.1194824.CrossRefPubMed

36.

Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27(21):R1147–51. https://doi.org/10.1016/j.cub.2017.09.019.CrossRefPubMedPubMedCentral

37.

Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5(1):58–58. https://doi.org/10.1038/s41572-019-0105-0.CrossRefPubMed

38.

Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis. 2017;21(1):1–20. https://doi.org/10.1016/j.cld.2016.08.001.CrossRefPubMed

39.

Ma XW, McKeen T, Zhang J, Ding WX. Role and mechanisms of mitophagy in liver diseases. Cells. 2020;9(4):837–837. https://doi.org/10.3390/cells9040837.CrossRefPubMedCentral

40.

Keil C, Maskos K, Than M, Hoopes JT, Huber R, Tan F, et al. Crystal structure of the human carboxypeptidase N (kininase I) catalytic domain. J Mol Biol. 2007;366(2):504–16. https://doi.org/10.1016/j.jmb.2006.11.025.CrossRefPubMed

Title: Carboxypeptidase N1 is anticipated to be a synergy metrics for chemotherapy effectiveness and prognostic significance in invasive breast cancer
Authors: Ranliang Cui
Chaomin Wang
Tiantian Li
Jialei Hua
Ting Zhao
Li Ren
Yichao Wang
Yueguo Li
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Cytostatic Therapy
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02256-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

LncRNA SNHG16 contributes to tumor progression via the miR-302b-3p/SLC2A4 axis in pancreatic adenocarcinoma

IRF4 overexpression promotes the transdifferentiation of tregs into macrophage‐like cells to inhibit the development of colon cancer

Identification of DNA repair-related genes predicting pathogenesis and prognosis for liver cancer

Preliminary study of 3 T-MRI native T1-mapping radiomics in differential diagnosis of non-calcified solid pulmonary nodules/masses

Recombinant immunotoxins development for HER2-based targeted cancer therapies

PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer